# Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

> **NCT04536805** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 44 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Metformin
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT) 30 Gray (Gy)
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT) 36 Gy
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT) 25 Gy

## Key facts

- **NCT ID:** NCT04536805
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-17
- **Primary completion:** 2031-11
- **Final completion:** 2031-11
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536805, "Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04536805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*